CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.
The firm moved closer to commercializing its lung transplant test, and it was notified by New York State that it could begin testing patient samples using its DTC celiac disease test.
CareDx said it will add XynManagement's products to its digital solutions portfolio and integrate them with current offerings including OTTR.
The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.
The company reported $31.5 million in total revenues for the quarter and said testing services revenues rose 84 percent year over year.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.
The diagnostic will now be a contracted service with Anthem Blue Cross of California and 10 of its affiliated health plans.
The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.
The acquisition of OTTR Complete Transplant Management will enable CareDx to integrate the EMRs of patients at transplant centers with longitudinal patient surveillance data.